

NEWPORT CORP  
Form 10-Q  
May 09, 2013  
[Table of Contents](#)

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

---

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 30, 2013**

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

**Commission File Number: 000-01649**

---

**NEWPORT CORPORATION**

Edgar Filing: NEWPORT CORP - Form 10-Q

*(Exact name of registrant as specified in its charter)*

**Nevada**

*(State or other jurisdiction of  
incorporation or organization)*

**94-0849175**

*(IRS Employer Identification No.)*

**1791 Deere Avenue, Irvine, California 92606**

*(Address of principal executive offices) (Zip Code)*

**(949) 863-3144**

*(Registrant's telephone number, including area code)*

**Not Applicable**

*(Former name, former address and former fiscal year, if changed since last report)*

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
Non-accelerated filer

Accelerated filer   
(Do not check if a smaller reporting company) Smaller reporting company

Edgar Filing: NEWPORT CORP - Form 10-Q

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

As of April 26, 2013, 39,080,464 shares of the registrant's sole class of common stock were outstanding.

|  |
|--|
|  |
|--|

Table of Contents

**NEWPORT CORPORATION**

**FORM 10-Q**

**INDEX**

|  | <b>Page<br/>Number</b>   |
|--|--|
| <b><u>PART I.</u></b>                    |  |
|  | <b><u>FINANCIAL INFORMATION</u></b>  |
| <u>Item 1.</u>                           | <u>Financial Statements (unaudited):</u>   |
|  | <u>Consolidated Statements of Income and Comprehensive Income for the Three Months Ended March 30, 2013 and March 31, 2012</u> |
|  | 3  |
|  | <u>Consolidated Balance Sheets as of March 30, 2013 and December 29, 2012</u>  |
|  | 4  |
|  | <u>Consolidated Statements of Cash Flows for the Three Months Ended March 30, 2013 and March 31, 2012</u>                      |
|  | 5  |
|  | <u>Notes to Consolidated Financial Statements</u>  |
|  | 6  |
| <u>Item 2.</u>                           | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>                                   |
|  | 18   |
| <u>Item 3.</u>                           | <u>Quantitative and Qualitative Disclosures About Market Risk</u>  |
|  | 24   |
| <u>Item 4.</u>                           | <u>Controls and Procedures</u>   |
|  | 26   |
| <b><u>PART II. OTHER INFORMATION</u></b> |  |
| <u>Item 1.</u>                           | <u>Legal Proceedings</u>   |
|  | 27   |
| <u>Item 6.</u>                           | <u>Exhibits</u>  |
|  | 27   |
| <b><u>SIGNATURES</u></b>                 | 28   |

Table of Contents**PART I FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****NEWPORT CORPORATION****Consolidated Statements of Income and Comprehensive Income****(In thousands, except per share data)****(Unaudited)**

|  | <b>Three Months Ended</b> |                           |
|--|---------------------------|---------------------------|
|  | <b>March 30,<br/>2013</b> | <b>March 31,<br/>2012</b> |
| Net sales  | \$ 132,607                | \$ 157,167                |
| Cost of sales  | 77,475                    | 89,098                    |
| Gross profit   | 55,132                    | 68,069                    |
| Selling, general and administrative expenses                 | 37,608                    | 44,060                    |
| Research and development expense                             | 13,101                    | 13,799                    |
| Operating income   | 4,423                     | 10,210                    |
| Interest and other expense, net                              | (2,137)                   | (2,187)                   |
| Income before income taxes                                   | 2,286                     | 8,023                     |
| Income tax provision (benefit)                               | (448)                     | 1,435                     |
| Net income   | 2,734                     | 6,588                     |
| Net loss attributable to non-controlling interests           | (12)                      | (4)                       |
| Net income attributable to Newport Corporation               | \$ 2,746                  | \$ 6,592                  |
| Net income   | \$ 2,734                  | \$ 6,588                  |
| Other comprehensive income:                                  |                           |                           |
| Foreign currency translation gains (losses)                  | (2,452)                   | 1,587                     |
| Unrecognized net pension gains (losses)                      | 190                       | (16)                      |
| Unrealized gains (losses) on marketable securities           | (98)                      | 33                        |
| Comprehensive income   | \$ 374                    | \$ 8,192                  |
| Comprehensive loss attributable to non-controlling interests | \$ (61)                   | \$ (46)                   |
| Comprehensive income attributable to Newport Corporation     | 435                       | 8,238                     |
| Comprehensive income   | \$ 374                    | \$ 8,192                  |
| Net income per share attributable to Newport Corporation:    |                           |                           |
| Basic  | \$ 0.07                   | \$ 0.17                   |
| Diluted  | \$ 0.07                   | \$ 0.17                   |
| Shares used in per share calculations:                       |                           |                           |
| Basic  | 38,601                    | 37,731                    |
| Diluted  | 39,260                    | 38,931                    |

See accompanying notes.

Table of Contents**NEWPORT CORPORATION****Consolidated Balance Sheets****(In thousands, except share and per share data)****(Unaudited)**

|   | <b>March 30,<br/>2013</b> |    | <b>December 29,<br/>2012</b> |
|---|---------------------------|----|------------------------------|
| <b>ASSETS</b>   |                           |    |                              |
| Current assets:   |                           |    |                              |
| Cash and cash equivalents   | \$ 83,846                 | \$ | 88,767                       |
| Restricted cash   | 3,122                     |    | 3,107                        |
| Marketable securities   | 9,205                     |    | 8,498                        |
| Accounts receivable, net of allowance for doubtful accounts of \$1,474 and \$1,548 as of March 30, 2013 and December 29, 2012, respectively   | 89,722                    |    | 89,445                       |
| Notes receivable  | 1,514                     |    | 1,536                        |
| Inventories   | 108,262                   |    | 108,728                      |
| Deferred income taxes   | 19,817                    |    | 19,872                       |
| Prepaid expenses and other current assets   | 18,111                    |    | 17,727                       |
| Total current assets  | 333,599                   |    | 337,680                      |
| Property and equipment, net   | 81,962                    |    | 82,843                       |
| Goodwill  | 79,388                    |    | 79,586                       |
| Deferred income taxes   | 5,456                     |    | 5,646                        |
| Intangible assets, net  | 74,651                    |    | 77,446                       |
| Investments and other assets  | 35,322                    |    | 37,760                       |
|   | \$ 610,378                | \$ | 620,961                      |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>   |                           |    |                              |
| Current liabilities:  |                           |    |                              |
| Short-term borrowings, net  | \$ 35,468                 | \$ | 32,985                       |
| Accounts payable  | 30,372                    |    | 31,061                       |
| Accrued payroll and related expenses  | 26,466                    |    | 29,096                       |
| Accrued expenses and other current liabilities  | 34,945                    |    | 34,696                       |
| Total current liabilities   | 127,251                   |    | 127,838                      |
| Long-term debt, net   | 136,170                   |    | 150,758                      |
| Accrued pension liabilities   | 26,561                    |    | 27,764                       |
| Deferred income taxes and other liabilities   | 22,925                    |    | 23,783                       |
| Commitments and contingencies   |                           |    |                              |
| Stockholders' equity:   |                           |    |                              |
| Common stock, par value \$0.1167 per share, 200,000,000 shares authorized; 38,810,704 and 38,402,291 shares issued and outstanding as of March 30, 2013 and December 29, 2012, respectively | 4,529                     |    | 4,481                        |
| Capital in excess of par value  | 447,305                   |    | 441,074                      |
| Accumulated other comprehensive loss  | (9,260)                   |    | (6,949)                      |
| Accumulated deficit   | (146,428)                 |    | (149,174)                    |
| Total stockholders' equity of Newport Corporation   | 296,146                   |    | 289,432                      |
| Non-controlling interests   | 1,325                     |    | 1,386                        |
| Total stockholders' equity  | 297,471                   |    | 290,818                      |
|   | \$ 610,378                | \$ | 620,961                      |

See accompanying notes.



Table of Contents

## NEWPORT CORPORATION

## Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

|   | Three Months Ended |                   |
|---|--------------------|-------------------|
|   | March 30,<br>2013  | March 31,<br>2012 |
| <b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>                                      |                    |                   |
| Net income  | \$ 2,734           | \$ 6,588          |
| Adjustments to reconcile net income to net cash provided by operating activities: |                    |                   |
| Depreciation and amortization   | 7,965              | 10,818            |
| Provision for losses on inventories   | 2,334              | 2,310             |
| Stock-based compensation expense  | 2,269              | 2,214             |
| Provision for doubtful accounts   | 15                 | 35                |
| Loss on disposal of property and equipment  | 61                 | 58                |
| Deferred income taxes   | (8)                | (1,326)           |
| Increase (decrease) in cash, net of acquisition, due to changes in:               |                    |                   |
| Accounts and notes receivable   | (1,782)            | (1,415)           |
| Inventories   | (2,363)            | (1,278)           |
| Prepaid expenses and other assets   | (449)              | (1,270)           |
| Accounts payable  | (330)              | 1,053             |
| Accrued payroll and related expenses  | (2,379)            | (5,979)           |
| Accrued expenses and other liabilities  | (289)              | 1,112             |
| Other long-term liabilities   | (328)              | 295               |
| Net cash provided by operating activities   | 7,450              | 13,215            |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>                                      |                    |                   |
| Purchase of property and equipment  | (3,951)            | (3,732)           |
| Restricted cash   | (53)               | 11,460            |
| Business acquisition, net of cash acquired  | -                  | (8,939)           |
| Refundable amounts related to business acquisition                                | -                  | (317)             |
| Purchase of marketable securities   | (2,346)            | (1,293)           |
| Proceeds from the sale of marketable securities                                   | 1,481              | 878               |
| Net cash used in investing activities   | (4,869)            | (1,943)           |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>                                      |                    |                   |
| Repayment of long-term debt and obligations under capital leases                  | (11,892)           | (9,376)           |
| Proceeds from short-term borrowings   | 1,599              | 3,280             |
| Repayment of short-term borrowings  | (876)              | (14,853)          |
| Proceeds from the issuance of common stock under employee plans                   | 4,010              | 2,001             |
| Tax withholding payments related to net share settlement of equity awards         | -                  | (3,053)           |
| Net cash used in financing activities   | (7,159)            | (22,001)          |
| Impact of foreign exchange rate changes on cash balances                          | (343)              | 298               |
| Net decrease in cash and cash equivalents   | (4,921)            | (10,431)          |
| Cash and cash equivalents at beginning of period                                  | 88,767             | 55,701            |
| Cash and cash equivalents at end of period  | \$ 83,846          | \$ 45,270         |
| Supplemental disclosures of cash flow information:                                |                    |                   |
| Cash paid during the period for interest  | \$ 1,927           | \$ 1,873          |
| Cash paid during the period for income taxes, net                                 | \$ 799             | \$ 1,299          |
| Property and equipment accrued in accounts payable                                | \$ 178             | \$ 20             |

See accompanying notes.



Table of Contents

**NEWPORT CORPORATION**

**Notes to Consolidated Financial Statements**

**March 30, 2013**

**NOTE 1 BASIS OF PRESENTATION**

The accompanying unaudited consolidated financial statements include the accounts of Newport Corporation and its wholly owned subsidiaries (collectively referred to as the Company) and have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions of Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal and recurring accruals) considered necessary for a fair presentation have been included. All intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited consolidated financial statements do not include certain footnotes and financial presentations normally required under generally accepted accounting principles (GAAP) and, therefore, should be read in conjunction with the consolidated financial statements and related notes contained in the Company's Annual Report on Form 10-K for the year ended December 29, 2012. The results for the interim periods are not necessarily indicative of the results the Company will have for the full year ending December 28, 2013. The December 29, 2012 balances reported herein are derived from the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 29, 2012.

Subsequent to the filing of the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2012, management determined that certain debt repayments and borrowings were both overstated by \$1.0 million in the Company's consolidated statement of cash flows for the three months ended March 31, 2012. In the consolidated statement of cash flows included in the accompanying unaudited consolidated financial statements, the Company corrected the presentation of *repayment of long-term debt and obligations under capital leases and proceeds from short-term borrowings* to accurately report debt repayments and borrowings. The Company believes that the effect of this adjustment is not material to the consolidated statement of cash flows for the three months ended March 31, 2012.

**NOTE 2 RECENT ACCOUNTING PRONOUNCEMENTS**

In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2013-02, *Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income*, which requires companies to disclose significant amounts that have been reclassified out of accumulated other comprehensive income. Amounts that are required to be reclassified in their entirety to net income must be disclosed either on the face of the income statement or in the notes to the financial statements. Amounts that are not required to be reclassified in their entirety to net income in the same reporting period must be disclosed by a cross reference to other disclosures that provide additional information regarding such amounts. ASU No. 2013-02 is effective for fiscal years and interim periods beginning after December 15, 2012. The adoption of ASU No. 2013-02 has not had a material impact on the Company's financial position or results of operations.

In March 2013, the FASB issued ASU No. 2013-05, *Foreign Currency Matters: Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity*, which clarifies the guidance in Topics 810 and 830. Topic 810 requires companies to deconsolidate a subsidiary or derecognize a group of assets if the parent ceases to hold a controlling financial interest in that subsidiary or group of assets. Upon the loss of a controlling financial interest, the parent would recognize the cumulative translation adjustment in net income. The guidance in Topic 810 does not distinguish between a sale or transfer of an investment *in* a foreign entity and a sale or transfer of a subsidiary or group of assets *within* a foreign entity. Topic 830 requires the release of the cumulative translation adjustment into net income if a sale or transfer represented a complete or substantially complete liquidation of an investment *in* a foreign entity. ASU No. 2013-05 clarifies that companies that cease to have a controlling financial interest in a subsidiary or group of assets *within* a foreign subsidiary should release the cumulative translation adjustment into net income if the sale or transfer results in a complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. ASU No. 2013-05 will be effective for fiscal years beginning after December 15, 2013, and early adoption is permitted but has not been elected by the Company. The adoption of ASU No. 2013-05 will not have a material impact on the Company's financial position or results of operations.

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

March 30, 2013

## NOTE 3 MARKETABLE SECURITIES

All marketable securities of the Company were classified as available for sale and were recorded at market value using the specific identification method, and unrealized gains and losses are reflected in *accumulated other comprehensive loss* in the accompanying consolidated balance sheets. The aggregate fair value of available for sale securities and the aggregate amount of unrealized gains and losses in available for sale securities at March 30, 2013 were as follows:

| (In thousands)          | Aggregate<br>Fair Value | Gains | Aggregate Amount of<br>Unrealized |    | Losses |
|-------------------------|-------------------------|-------|-----------------------------------|----|--------|
|                         |                         |       |                                   |    |        |
| Money market funds      | \$ 4,923                | \$    | 83                                | \$ | -      |
| Certificates of deposit | 4,282                   |       | -                                 |    | -      |
|                         | \$ 9,205                | \$    | 83                                | \$ | -      |

The aggregate fair value of available for sale securities and the aggregate amount of unrealized gains and losses in available for sale securities at December 29, 2012 were as follows:

| (In thousands)          | Aggregate<br>Fair Value | Gains | Aggregate Amount of<br>Unrealized |    | Losses |
|-------------------------|-------------------------|-------|-----------------------------------|----|--------|
|                         |                         |       |                                   |    |        |
| Money market funds      | \$ 4,244                | \$    | 86                                | \$ | -      |
| Certificates of deposit | 4,254                   |       | -                                 |    | -      |
|                         | \$ 8,498                | \$    | 86                                | \$ | -      |

The contractual maturities of certificates of deposit were as follows:

| (In thousands)     | March 30,<br>2013 |       |
|--------------------|-------------------|-------|
| 0 - 1 Year         | \$                | 4,282 |
| 1 - 2 Years        |                   | -     |
| 2 - 3 Years        |                   | -     |
| 3 - 5 Years        |                   | -     |
| 5 - 10 Years       |                   | -     |
| More than 10 years |                   | -     |
|                    | \$                | 4,282 |

There were no realized gains or losses on the sale of available for sale securities for the three months ended March 30, 2013 or the three months ended March 31, 2012.

**NOTE 4                    FAIR VALUE MEASUREMENTS**

ASC 820-10, *Fair Value Measurements and Disclosures*, requires that for any assets and liabilities stated at fair value on a recurring basis in the Company's financial statements, the fair value of such assets and liabilities be measured based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Level 1 asset and liability values are derived from quoted prices in active markets for identical assets and liabilities and Level 2 asset and liability values are derived from quoted prices in inactive markets or based on other observable inputs.

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

March 30, 2013

The Company's assets and liabilities measured at fair value on a recurring basis are categorized in the table below based upon their level within the fair value hierarchy as of March 30, 2013.

| (In thousands)                         | Description | March 30, 2013 | Fair Value Measurements at Reporting Date Using |                   |              |        |
|--|-------------|----------------|---|-------------------|--------------|--------|
|  |             |                | Quoted Prices in                                |                   | Significant  |        |
|  |             |                | Active Markets for                              | Significant Other | Unobservable |        |
|  |             |                | Identical Assets                                | Observable Inputs | Inputs       |        |
|  |             |                | (Level 1)                                       | (Level 2)         | (Level 3)    |        |
| Assets:                                |             |                |   |                   |              |        |
| Restricted Cash                        | \$          | 3,122          | \$  | 3,122             | \$           | -      |
| Marketable securities:                 |             |                |   |                   |              |        |
| Money market funds                     |             | 4,923          |   | 4,923             |              | -      |
| Certificates of deposit                |             | 4,282          |   | -                 | 4,282        | -      |
|  |             | 9,205          |   | 4,923             | 4,282        | -      |
| Derivative assets:                     |             |                |   |                   |              |        |
| Forward contracts                      |             | 8              |   | -                 | 8            | -      |
| Option contracts                       |             | 701            |   | -                 | 701          | -      |
|  |             | 709            |   | -                 | 709          | -      |
| Funds in investments and other assets: |             |                |   |                   |              |        |
| Israeli pension funds                  |             | 10,344         |   | -                 | 10,344       | -      |
| Pension assets not owned by plan       |             | 6,541          |   | -                 | 6,541        | -      |
|  |             | 16,885         |   | -                 | 16,885       | -      |
|  | \$          | 29,921         | \$  | 8,045             | \$           | 21,876 |
| Liabilities:                           |             |                |   |                   |              |        |
| Derivative liabilities:                |             |                |   |                   |              |        |
| Option contracts                       |             | 109            |   | -                 | 109          | -      |

The Company's assets and liabilities measured at fair value on a recurring basis are categorized in the table below based upon their level within the fair value hierarchy as of December 29, 2012.

| (In thousands) | Description | December 29, 2012 | Fair Value Measurements at Reporting Date Using |                   |              |
|----------------|-------------|-------------------|---|-------------------|--------------|
|                |             |                   | Quoted Prices in                                |                   | Significant  |
|                |             |                   | Active Markets for                              | Significant Other | Unobservable |
|                |             |                   | Identical Assets                                | (Level 2)         | Inputs       |
|                |             |                   |   |                   |              |

Edgar Filing: NEWPORT CORP - Form 10-Q

|  | (Level 1) |        |    | (Level 3) |    |        |
|--|-----------|--------|----|-----------|----|--------|
| Assets:                                |           |        |    |           |    |        |
| Restricted Cash                        | \$        | 3,107  | \$ | 3,107     | \$ | -      |
| Marketable securities:                 |           |        |    |           |    |        |
| Money market funds                     |           | 4,244  |    | 4,244     |    | -      |
| Certificates of deposit                |           | 4,254  |    | -         |    | 4,254  |
|  |           | 8,498  |    | 4,244     |    | 4,254  |
| Derivative assets:                     |           |        |    |           |    |        |
| Option contracts                       |           | 755    |    | -         |    | 755    |
| Funds in investments and other assets: |           |        |    |           |    |        |
| Israeli pension funds                  |           | 10,690 |    | -         |    | 10,690 |
| Pension assets not owned by plan       |           | 6,615  |    | -         |    | 6,615  |
|  |           | 17,305 |    | -         |    | 17,305 |
|  | \$        | 29,665 | \$ | 7,351     | \$ | 22,314 |
| Liabilities:                           |           |        |    |           |    |        |
| Derivative liabilities:                |           |        |    |           |    |        |
| Option contracts                       |           | 202    |    | -         |    | 202    |



Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

March 30, 2013

The Company's other financial instruments include short-term borrowings and long-term debt. The fair value of these financial instruments was estimated based on current rates for similar issues or on the current rates offered to the Company for debt of similar remaining maturities. The estimated fair values of these financial instruments were as follows:

| (In thousands)        | March 30, 2013  |            | December 29, 2012 |            |
|-----------------------|-----------------|------------|-------------------|------------|
|                       | Carrying Amount | Fair Value | Carrying Amount   | Fair Value |
| Short-term borrowings | \$ 35,468       | \$ 34,235  | \$ 32,985         | \$ 32,020  |
| Long-term debt        | \$ 136,170      | \$ 130,271 | \$ 150,758        | \$ 145,404 |

## NOTE 5 SUPPLEMENTAL BALANCE SHEET INFORMATION

*Inventories*

Inventories that are expected to be sold within one year are classified as current inventories and are included in *inventories* in the accompanying consolidated balance sheets. Such inventories were as follows:

| (In thousands)                    | March 30, 2013 | December 29, 2012 |
|-----------------------------------|----------------|-------------------|
| Raw materials and purchased parts | \$ 64,261      | \$ 65,766         |
| Work in process                   | 17,537         | 18,075            |
| Finished goods                    | 26,464         | 24,887            |
| Short-term inventories            | \$ 108,262     | \$ 108,728        |

Inventories that are not expected to be sold within one year are classified as long-term inventories and are included in *investments and other assets* in the accompanying consolidated balance sheets. Such inventories were as follows:

| (In thousands)                    | March 30, 2013 | December 29, 2012 |
|-----------------------------------|----------------|-------------------|
| Raw materials and purchased parts | \$ 3,300       | \$ 4,149          |
| Finished goods                    | 4,540          | 4,926             |
| Long-term inventories             | \$ 7,840       | \$ 9,075          |

*Accrued Warranty Obligations*

Unless otherwise stated in the Company's product literature or in its agreements with customers, products sold by the Company's Photonics and Optics Groups generally carry a one-year warranty from the original invoice date on all product materials and workmanship, other than filters and gratings products, which generally carry a 90-day warranty and laser beam profilers and dental CAD/CAM scanners, which generally carry a two-year warranty. Products of these groups sold to original equipment manufacturer (OEM) customers generally carry longer warranties, typically 15 to 19 months. Products sold by the Company's Lasers Group carry warranties that vary by product and product component, but generally range from 90 days to two years. In certain cases, such warranties for Lasers Group products are limited by either a set time period or a maximum amount of hourly usage of the product, whichever occurs first. Defective products will be either repaired or replaced, generally at the Company's option, upon meeting certain criteria. The Company accrues a provision for the estimated costs that may be incurred for warranties relating to a product (based on historical experience) as a component of cost of sales. Short-term accrued warranty obligations, which expire within one year, are included in *accrued expenses and other current liabilities* and long-term warranty obligations are included in *deferred income taxes and other liabilities* in the accompanying consolidated balance sheets. Short-term warranty obligations were \$3.3 million and \$3.4 million as of March 30, 2013 and December 29, 2012, respectively. As of March 30, 2013 and December 29, 2012, the amounts accrued for long-term warranty obligations were not material.

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

March 30, 2013

The activity in accrued warranty obligations was as follows:

| (In thousands)                     | Three Months Ended |                   |
|------------------------------------|--------------------|-------------------|
|                                    | March 30,<br>2013  | March 31,<br>2012 |
| Balance at beginning of year       | \$ 3,528           | \$ 4,466          |
| Additions charged to cost of sales | 596                | 629               |
| Additions from acquisitions        | -                  | 21                |
| Warranty claims                    | (742)              | (1,195)           |
| Balance at end of period           | \$ 3,382           | \$ 3,921          |

*Accrued Expenses and Other Current Liabilities*

Accrued expenses and other current liabilities were as follows:

| (In thousands)                          | March 30,<br>2013 | December 29,<br>2012 |
|---|-------------------|----------------------|
|   | Deferred revenue  | \$ 12,702            |
| Deferred lease liability                | 5,464             | 5,445                |
| Accrued and deferred taxes              | 3,714             | 3,866                |
| Short-term accrued warranty obligations | 3,251             | 3,421                |
| Other                                   | 9,814             | 10,403               |
|   | \$ 34,945         | \$ 34,696            |

*Accumulated Other Comprehensive Loss*

Accumulated other comprehensive loss consisted of the following:

| (In thousands)                            | March 30,<br>2013                              | December 29,<br>2012 |
|---|--|----------------------|
|   | Cumulative foreign currency translation losses | \$ (6,972)           |
| Unrecognized net pension losses           | (3,058)  | (3,248)              |
| Unrealized gains on marketable securities | 770  | 868                  |
|   | \$ (9,260)                                     | \$ (6,949)           |



Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

March 30, 2013

**NOTE 6 INTANGIBLE ASSETS**

Intangible assets were as follows:

| (In thousands)   | March 30,<br>2013 | December 29,<br>2012 |
|--|-------------------|----------------------|
| Intangible assets subject to amortization:   |                   |                      |
| Developed technology, net of accumulated amortization of \$11,638 and \$10,885 as of March 30, 2013 and December 29, 2012, respectively          | \$ 28,797         | \$ 29,742            |
| Customer relationships, net of accumulated amortization of \$27,827 and \$26,255 as of March 30, 2013 and December 29, 2012, respectively        | 18,487            | 20,100               |
| In-process research and development, net of accumulated amortization of \$280 and \$158 as of March 30, 2013 and December 29, 2012, respectively | 7,611             | 7,746                |
| Other, net of accumulated amortization of \$5,916 and \$5,915 as of March 30, 2013 and December 29, 2012, respectively                           | 1,451             | 1,553                |
|  | 56,346            | 59,141               |
| Intangible assets not subject to amortization:   |                   |                      |
| Trademarks and trade names   | 18,305            | 18,305               |
| Intangible assets, net   | \$ 74,651         | \$ 77,446            |

Developed technology is amortized on a straight line basis over 10 to 20 years, depending on the life of the product technology. Intangible assets related to customer relationships are generally amortized over a period of up to 10 years on an accelerated basis. In-process research and development is amortized on a straight line basis over the product's estimated useful life upon completion of the technology. Other intangible assets include acquired backlog, product trademarks and trade names, non-competition agreements and defensible assets. With the exception of product trademarks and trade names, such assets are amortized on a straight line basis over a period of three months to 10 years, depending on the asset. Trademarks and trade names associated with products are amortized on a straight line basis over the estimated remaining life of the product technology, which ranges from 10 to 20 years. Trademarks and trade names associated with a business have indefinite lives and are not amortized.

Amortization expense related to intangible assets totaled \$2.6 million for the three months ended March 30, 2013 and \$5.2 million for the three months ended March 31, 2012.

Table of Contents

**NEWPORT CORPORATION**

**Notes to Consolidated Financial Statements**

**March 30, 2013**

Estimated aggregate amortization expense for future fiscal years is as follows:

| <b>(In thousands)</b> | <b>Estimated<br/>Aggregate<br/>Amortization<br/>Expense</b> |
|-----------------------|---|
| 2013 (remaining)      | \$ 7,751  |
| 2014                  | 8,344   |
| 2015                  | 6,712   |
| 2016                  | 6,337   |
| 2017                  | 5,371   |
| Thereafter            | 19,863  |
|                       | <b>\$ 54,378</b>  |

The Company has excluded \$2.0 million of amortization expense related to certain in-process research and development projects from the table above, as it was uncertain as of March 30, 2013 when the technology will be completed and when the amortization will begin.

**NOTE 7 INTEREST AND OTHER EXPENSE, NET**

Interest and other expense, net, was as follows:

| <b>(In thousands)</b>                    | <b>Three Months Ended</b> |                           |
|--|---------------------------|---------------------------|
|  | <b>March 30,<br/>2013</b> | <b>March 31,<br/>2012</b> |
| Interest expense                         | \$ (1,789)                | \$ (2,201)                |
| Interest and dividend income             | 49                        | 61                        |
| Derivative gain                          | 202                       | 671                       |
| Bank and portfolio asset management fees | (192)                     | (164)                     |
| Other expense, net                       | (407)                     | (554)                     |
|  | <b>\$ (2,137)</b>         | <b>\$ (2,187)</b>         |

**NOTE 8 STOCK-BASED COMPENSATION**

## Edgar Filing: NEWPORT CORP - Form 10-Q

The total stock-based compensation expense included in the Company's consolidated statements of income and comprehensive income was as follows:

| (In thousands)                               | Three Months Ended |                   |
|--|--------------------|-------------------|
|  | March 30,<br>2013  | March 31,<br>2012 |
| Cost of sales                                | \$ 209             | \$ 117            |
| Selling, general and administrative expenses | 1,820              | 1,839             |
| Research and development expense             | 240                | 258               |
|  | \$ 2,269           | \$ 2,214          |

At March 30, 2013, the total compensation cost related to unvested stock-based awards granted to employees, officers and directors under the Company's stock-based benefit plans that had not yet been recognized was \$7.6 million (net of estimated forfeitures of \$1.5 million). This future compensation expense will be amortized over a weighted-average period of 1.4 years using the straight-line attribution method. The actual compensation expense that the Company will recognize in the future related to unvested stock-based awards outstanding at March 30, 2013 will be adjusted for actual forfeitures.

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

March 30, 2013

At March 30, 2013, 0.7 million stock options with a weighted-average exercise price of \$14.58 per share, intrinsic value of \$1.5 million and remaining contractual term of 1.4 years were outstanding and were exercisable. At March 30, 2013, 1.4 million stock-settled stock appreciation rights with a weighted-average base value of \$11.47 per share, intrinsic value of \$8.0 million and remaining contractual term of 4.4 years were outstanding, and 0.8 million stock-settled stock appreciation rights with a weighted-average base value of \$7.23 per share, intrinsic value of \$7.5 million and remaining contractual term of 3.4 years were exercisable.

**NOTE 9 DEBT AND LINES OF CREDIT**

Total short-term debt was as follows:

| (In thousands)                            | March 30,<br>2013 | December 29,<br>2012 |
|---|-------------------|----------------------|
| Japanese revolving lines of credit        | \$ 5,307          | \$ 5,231             |
| Japanese receivables financing facilities | 551               | 415                  |
| Total short-term borrowings               | \$ 5,858          | \$ 5,646             |

Total long-term debt was as follows:

| (In thousands)                                 | March 30,<br>2013 | December 29,<br>2012 |
|--|-------------------|----------------------|
| U.S. term loan due October 2016                | \$ 159,563        | \$ 171,125           |
| Israeli loans due through October 2015         | 3,230             | 3,591                |
| Japanese private placement bonds due June 2014 | 2,122             | 2,325                |
| Japanese loans due through November 2016       | 865               | 1,056                |
| Total long-term debt                           | 165,780           | 178,097              |
| Current portion of long-term debt              | 29,610            | 27,339               |
| Total long-term debt, less current portion     | \$ 136,170        | \$ 150,758           |



Table of Contents**NEWPORT CORPORATION****Notes to Consolidated Financial Statements****March 30, 2013****NOTE 10 NET INCOME PER SHARE**

The following table sets forth the computation of basic and diluted net income per share:

| (In thousands, except per share data)                         | Three Months Ended |                   |
|---|--------------------|-------------------|
|   | March 30,<br>2013  | March 31,<br>2012 |
| Net income attributable to Newport Corporation                | \$ 2,746           | \$ 6,592          |
| Shares:   |                    |                   |
| Weighted average shares outstanding - basic                   | 38,601             | 37,731            |
| Dilutive potential common shares, using treasury stock method | 659                | 1,200             |
| Weighted average shares outstanding - diluted                 | 39,260             | 38,931            |
| Net income per share attributable to Newport Corporation:     |                    |                   |
| Basic   | \$ 0.07            | \$ 0.17           |
| Diluted   | \$ 0.07            | \$ 0.17           |

For the three months ended March 30, 2013, an aggregate of 0.9 million stock options and stock appreciation rights were excluded from the computations of diluted net income per share, as their exercise prices (or base values) exceeded the average market price of the Company's common stock during such periods, and their inclusion would have been antidilutive. For the three months ended March 30, 2013, 0.4 million restricted stock units were excluded from the computations of diluted net income per share, as the amount of unrecognized future compensation expense associated with these restricted stock units would have resulted in assumed proceeds in excess of the amount required to repurchase the underlying shares under the treasury stock method and, therefore, their inclusion would have been antidilutive.

**NOTE 11 INCOME TAXES**

Under ASC 740-270, *Income Taxes - Interim Reporting*, the Company is required to evaluate and make any necessary adjustments to its effective tax rate each quarter as new information is obtained that may affect the assumptions used to estimate its annual effective tax rate. The Company's assumptions relate to factors such as the projected level and mix of pre-tax earnings in the various tax jurisdictions in which it operates, valuation allowances against deferred tax assets, the recognition or derecognition of tax benefits related to uncertain tax positions, expected utilization of tax credits and changes in or the interpretation of tax laws in jurisdictions in which the Company conducts business. In addition, jurisdictions for which the Company has projected losses for the year, or a year-to-date loss, where no tax benefit can be recognized, are excluded from the calculation of the estimated annual effective tax rate. Changes in the assumptions and the inclusion or exclusion of certain jurisdictions could result in a higher or lower effective tax rate during a particular quarter.

Deferred income taxes are recognized for the future tax consequences of temporary differences using enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Temporary differences include the difference between the financial statement carrying amounts and the tax bases of existing assets and liabilities and operating loss and tax credit carryforwards. The effect of a change in tax rates on deferred taxes is recognized in income in the period that includes the enactment date. In accordance with the provisions of ASC 740, a valuation allowance for deferred tax assets is recorded to the extent the Company cannot determine that the ultimate realization of the net deferred tax assets is more likely than not. Realization of deferred tax assets is principally dependent upon the achievement of future taxable income, the estimation of which requires significant management judgment. As of March 30, 2013, the Company could not determine that it is more likely than not that deferred tax assets related to certain domestic and foreign net operating loss carryforwards and certain other miscellaneous domestic and foreign deferred tax assets would be realized. Therefore, the Company has maintained a valuation allowance of \$3.3 million against its domestic and certain foreign subsidiaries' deferred tax assets.

Table of Contents

**NEWPORT CORPORATION**

**Notes to Consolidated Financial Statements**

**March 30, 2013**

The Company utilizes ASC 740-10-25, *Income Taxes - Recognition*, which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under ASC 740-10-25, tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met. As a multi-national corporation, the Company is subject to taxation in many jurisdictions, and the calculation of its tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in various taxing jurisdictions. If the Company ultimately determines that the payment of these liabilities will be unnecessary, it reverses the liability and recognizes a tax benefit during the period in which it determines the liability no longer applies. Conversely, the Company records additional tax charges in a period in which it determines that a recorded tax liability is less than it expects the ultimate assessment to be. As a result of these adjustments, the Company's effective tax rate in a given financial statement period could be materially affected. During the three months ended March 30, 2013, the Company reversed \$0.7 million of unrecognized tax benefits related to a Japanese subsidiary, due to the expiration of the applicable audit statute of limitations. As of March 30, 2013, the Company had \$14.5 million of gross unrecognized tax benefits and a total of \$11.7 million of net unrecognized tax benefits, which, if recognized, would affect the effective tax rate. Interest and penalties related to unrecognized tax benefits were not significant for the three months ended March 30, 2013.

**NOTE 12 STOCKHOLDERS EQUITY TRANSACTIONS**

In May 2008, the Board of Directors of the Company approved a share repurchase program, authorizing the purchase of up to 4.0 million shares of the Company's common stock. No purchases were made under this program during the three months ended March 30, 2013. As of March 30, 2013, 3.9 million shares remained available for purchase under the program. However, the terms of the Company's senior secured credit facility entered into in October 2011 restrict the Company's ability to purchase additional shares under this program during the term of such facility.

**NOTE 13 DEFINED BENEFIT PENSION PLANS**

The Company has defined benefit pension plans covering substantially all full-time employees in France, Germany, Israel and Japan. In addition, the Company has certain pension liabilities relating to former employees of the Company in the United Kingdom. The German plan is unfunded, as permitted under the plan and applicable laws. For financial reporting purposes, the calculation of net periodic pension costs is based upon a number of actuarial assumptions, including a discount rate for plan obligations, an assumed rate of return on pension plan assets and an assumed rate of compensation increase for employees covered by the plan. All of these assumptions are based upon management's judgment, considering all known trends and uncertainties. Actual results that differ from these assumptions would impact future expense recognition and the cash funding requirements of the Company's pension plans.

Net periodic benefit costs for the plans in aggregate included the following components:

Edgar Filing: NEWPORT CORP - Form 10-Q

| (In thousands)                       | Three Months Ended |      |                   |      |
|--------------------------------------|--------------------|------|-------------------|------|
|                                      | March 30,<br>2013  |      | March 31,<br>2012 |      |
| Service cost                         | \$                 | 721  | \$                | 589  |
| Interest cost on benefit obligations |                    | 165  |                   | 185  |
| Expected return on plan assets       |                    | (52) |                   | (57) |
| Amortization of net loss             |                    | 63   |                   | 27   |
|                                      | \$                 | 897  | \$                | 744  |

Table of Contents**NEWPORT CORPORATION****Notes to Consolidated Financial Statements****March 30, 2013****NOTE 14 BUSINESS SEGMENT INFORMATION**

The operating segments reported below are the segments of the Company for which separate financial information is available and for which operating results are evaluated regularly by the Chief Executive Officer, who is the chief operating decision maker, in deciding how to allocate resources and in assessing performance. Prior to 2013, the Company developed, manufactured and marketed its products within three distinct business segments: its Lasers Division, its Photonics and Precision Technologies Division and its Ophir Division. In January 2013, the Company reorganized its operations to create three new operating segments: its Photonics Group, its Lasers Group and its Optics Group. As a result, the Company has revised its reportable segments to correspond with its new operating segments, reflecting the manner in which it now assesses performance and allocates resources. The results of operations of the Company's reportable segments for the three months ended March 31, 2012 reported below have been restated to conform to the new reportable segments.

The Company measured income reported for each business segment, which included only those costs that were directly attributable to the operations of that segment, and excluded certain unallocated operating expenses, such as corporate overhead and intangible asset amortization, interest and other expense, net, and income taxes.

| <b>(In thousands)</b>              | <b>Photonics</b> |        | <b>Lasers</b> |        | <b>Optics</b> |        | <b>Total</b> |
|------------------------------------|------------------|--------|---------------|--------|---------------|--------|--------------|
| Three months ended March 30, 2013: |                  |        |               |        |               |        |              |
| Sales to external customers        | \$               | 58,367 | \$            | 38,885 | \$            | 35,355 | \$ 132,607   |
| Segment income                     | \$               | 12,566 | \$            | 3,133  | \$            | 700    | \$ 16,399    |
| Three months ended March 31, 2012: |                  |        |               |        |               |        |              |
| Sales to external customers        | \$               | 60,132 | \$            | 49,227 | \$            | 47,808 | \$ 157,167   |
| Segment income                     | \$               | 12,280 | \$            | 6,683  | \$            | 6,189  | \$ 25,152    |

The following table reconciles segment income to consolidated income before income taxes:

| <b>(In thousands)</b>           | <b>Three Months Ended</b> |                           |
|---------------------------------|---------------------------|---------------------------|
|                                 | <b>March 30,<br/>2013</b> | <b>March 31,<br/>2012</b> |
| Segment income                  | \$ 16,399                 | \$ 25,152                 |
| Unallocated operating expenses  | (11,976)                  | (14,942)                  |
| Interest and other expense, net | (2,137)                   | (2,187)                   |
|                                 | \$ 2,286                  | \$ 8,023                  |

Table of Contents

**NEWPORT CORPORATION**

**Notes to Consolidated Financial Statements**

**March 30, 2013**

**NOTE 15 LEGAL PROCEEDINGS**

In November 2010, two former employees of Spectra-Physics, Linda Pope and Yvette Flores, together with their children, Tia Pope Hudson and Mark Flores, filed a complaint against Spectra-Physics and the Company in the Superior Court for Santa Clara County, California. In the action, the plaintiffs allege that between 1975 and 1985 they and their unborn children were exposed to toxic chemicals during their work at Spectra-Physics, and that Spectra-Physics failed to warn them about dangers associated with the chemicals and failed to implement adequate safeguards to protect them from the chemicals, resulting in injuries to them and their unborn children.

In November 2012, the Company reached an agreement with Linda Pope and Tia Pope Hudson to settle all claims related to their portion of the suit. The amount of such settlement was immaterial. In December 2012, the court denied the Company's motions for summary judgment of Yvette and Mark Flores' claims based on the statute of limitations applicable to such claims. The Company subsequently filed motions for summary judgment or summary adjudication of the plaintiffs' remaining claims based on additional grounds, and the plaintiffs have filed a motion for summary adjudication of certain of the Company's affirmative defenses to the plaintiffs' claims, which motions are scheduled to be heard in June 2013. Trial is currently set to commence in July 2013.

Yvette and Mark Flores are seeking an aggregate of \$20.5 million in general and special damages, as well as punitive damages for each of them to be established by the trier of fact. The Company disputes that the plaintiffs are entitled to any damages, and it continues to believe that the plaintiffs' claims are without merit and intends to continue to vigorously defend its position. Further, discovery in the action is ongoing, and the motions for summary judgment or adjudication filed by the Company and the plaintiffs are pending. Therefore, at this stage of the litigation, the Company is unable to provide an estimate of the potential exposure or the likelihood of a favorable or unfavorable outcome in this action.

Table of Contents

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*This Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our unaudited consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and in conjunction with our Annual Report on Form 10-K for the year ended December 29, 2012 previously filed with the SEC. This discussion contains descriptions of our expectations regarding future trends affecting our business. Words such as anticipate, believe, can, continue, could, estimate, expect, may, plan, potential, predict, should or the illegitimate word, other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance or condition, trends in our business, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements and other forward-looking statements made elsewhere in this report are made in reliance upon safe harbor provisions in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of several factors, including, but not limited to those factors set forth and discussed elsewhere in this Quarterly Report on Form 10-Q and in Item 1 (Business) and Item 1A (Risk Factors) of Part I, and Item 7 (Management's Discussion and Analysis of Financial Condition and Results of Operations) of Part II, of our Annual Report on Form 10-K for the year ended December 29, 2012. In light of the significant uncertainties inherent in the forward-looking information included in this report, the inclusion of this information should not be regarded as a representation by us or any other person that our objectives or plans will be achieved and readers are cautioned not to place undue reliance on such forward-looking information. Except as required by law, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.*

**Overview**

We are a global supplier of advanced-technology products and systems, including lasers, photonics instrumentation, precision positioning and vibration isolation products and systems, optical components, subassemblies and subsystems, three-dimensional non-contact measurement equipment and advanced automated manufacturing systems. Our products are used worldwide in a variety of industries including scientific research, defense and security, microelectronics, life and health sciences and industrial markets. Prior to 2013, we operated within three distinct business segments: our Lasers Division, our Photonics and Precision Technologies Division and our Ophir Division. In January 2013, we reorganized our operations to create three new operating groups: our Photonics Group, our Lasers Group and our Optics Group. All of these groups offer a broad array of advanced technology products and services to original equipment manufacturer (OEM) and end-user customers across a wide range of applications in all of our targeted end markets.

The following is a discussion and analysis of certain factors that have affected our results of operations and financial condition during the periods included in the accompanying consolidated financial statements.

**Critical Accounting Policies and Estimates**

The preparation of our financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We evaluate these estimates and assumptions on an ongoing basis. We base our estimates on our historical experience and on various other factors which we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the amounts of certain expenses that are not readily apparent from other sources. The accounting policies that involve the most significant judgments, assumptions and estimates used in the preparation of our

## Edgar Filing: NEWPORT CORP - Form 10-Q

financial statements are those related to revenue recognition, allowances for doubtful accounts, pension liabilities, inventory reserves, warranty obligations, asset impairment, income taxes and stock-based compensation. The judgments, assumptions and estimates used in these areas by their nature involve risks and uncertainties, and in the event that any of them prove to be inaccurate in any material respect, it could have a material effect on our reported amounts of assets and liabilities at the date of the financial statements and on the reported amounts of revenues and expenses during the reporting periods. A summary of these critical accounting policies is included in Item 7 (Management's Discussion and Analysis of Financial Condition and Results of Operations) of Part II of our Annual Report on Form 10-K for the fiscal year ended December 29, 2012. There have been no material changes to the critical accounting policies disclosed in our Annual Report on Form 10-K.



Table of Contents**Stock-Based Compensation**

The total stock-based compensation expense included in our consolidated statements of income and comprehensive income was as follows:

| (In thousands)                               | Three Months Ended |                   |
|--|--------------------|-------------------|
|  | March 30,<br>2013  | March 31,<br>2012 |
| Cost of sales                                | \$ 209             | \$ 117            |
| Selling, general and administrative expenses | 1,820              | 1,839             |
| Research and development expense             | 240                | 258               |
|  | \$ 2,269           | \$ 2,214          |

**Results of Operations for the Three Months Ended March 30, 2013 and March 31, 2012**

The following table presents our results of operations for the periods indicated as a percentage of net sales:

|  | Percentage of Net Sales |                   |
|--|-------------------------|-------------------|
|  | March 30,<br>2013       | March 31,<br>2012 |
| Net sales  | 100.0 %                 | 100.0 %           |
| Cost of sales                                      | 58.4                    | 56.7              |
| Gross profit                                       | 41.6                    | 43.3              |
| Selling, general and administrative expenses       | 28.4                    | 28.0              |
| Research and development expense                   | 9.9                     | 8.8               |
| Operating income                                   | 3.3                     | 6.5               |
| Interest and other expense, net                    | (1.6)                   | (1.4)             |
| Income before income taxes                         | 1.7                     | 5.1               |
| Income tax provision (benefit)                     | (0.3)                   | 0.9               |
| Net income   | 2.0                     | 4.2               |
| Net loss attributable to non-controlling interests | (0.0)                   | (0.0)             |
| Net income attributable to Newport Corporation     | 2.0 %                   | 4.2 %             |

In the following discussion regarding our results of operations, certain prior period amounts have been restated to conform to our current operating groups. In addition, in the following discussion regarding our net sales, due to changes in our market classifications for certain of our customers and product applications, certain prior period amounts have been reclassified among our end markets to conform to the current period presentation.

**Net Sales**

## Edgar Filing: NEWPORT CORP - Form 10-Q

Net sales for the three months ended March 30, 2013 decreased by \$24.6 million, or 15.6%, compared with the corresponding period in 2012. For the three months ended March 30, 2013, net sales by our Photonics Group decreased \$1.8 million, or 2.9%; net sales by our Lasers Group decreased \$10.3 million, or 21.0%; and net sales by our Optics Group decreased \$12.5 million, or 26.0%, compared with the corresponding prior year period. For the three months ended March 30, 2013, we experienced decreases in net sales to all of our end markets compared with the corresponding period in 2012.

Table of Contents

Net sales to the scientific research market for the three months ended March 30, 2013 decreased \$5.1 million, or 14.2%, compared with the same period in 2012, due primarily to decreased sales of laser products. Net sales to the defense and security markets for the three months ended March 30, 2013 decreased by \$2.0 million, or 11.3%, compared with the same period in 2012, due primarily to decreased sales of optics products. Net sales to these markets were impacted by adverse macroeconomic conditions as a result of budget constraints and uncertainty in future global research and defense spending levels. Generally, our net sales to these markets by each of our operating groups may fluctuate from period to period due to changes in overall research and defense spending levels and the timing of large sales relating to major research and defense programs and, in some cases, these fluctuations may be offsetting between our operating groups or between such periods.

Net sales to the microelectronics market for the three months ended March 30, 2013 decreased \$8.4 million, or 23.3%, compared with the same period in 2012. The decrease in sales to this market was due primarily to decreased sales of optics and precision motion products resulting from the continued cyclical downturn in the semiconductor equipment industry.

Net sales to the life and health sciences market for the three months ended March 30, 2013 decreased \$5.9 million, or 16.0%, compared with the same period in 2012. The decrease in sales to this market was due primarily to lower sales of lasers for bioimaging and surgical applications, and lower sales of optics products for analytical instrumentation applications.

Net sales to our industrial manufacturing and other end markets for the three months ended March 30, 2013 decreased \$3.1 million, or 10.2%, compared with the same period in 2012. The decrease in sales to these markets was due primarily to lower sales of products used for graphics, automotive safety and fiber optic communications applications due to weak macroeconomic conditions.

Table of Contents

The table below reflects our net sales by geographic region. Sales are attributed to each location based on the customer address to which the product is shipped.

| (In thousands)              | Three Months Ended |                | Decrease    | Percentage Decrease |
|-----------------------------|--------------------|----------------|-------------|---------------------|
|                             | March 30, 2013     | March 31, 2012 |             |                     |
| United States               | \$ 50,069          | \$ 61,195      | \$ (11,126) | (18.2) %            |
| Germany                     | 16,421             | 20,546         | (4,125)     | (20.1)              |
| Other European countries    | 19,373             | 20,647         | (1,274)     | (6.2)               |
| Japan                       | 14,095             | 18,043         | (3,948)     | (21.9)              |
| Other Pacific Rim countries | 22,572             | 24,500         | (1,928)     | (7.9)               |
| Rest of world               | 10,077             | 12,236         | (2,159)     | (17.6)              |
|                             | \$ 132,607         | \$ 157,167     | \$ (24,560) | (15.6) %            |

The decreases in sales to customers in the United States and Germany for the three months ended March 30, 2013 compared with the corresponding period in 2012 were attributable primarily to lower sales to our life and health sciences and our microelectronics end markets. To a lesser extent, sales in the United States decreased due to lower sales to our defense and security end markets, offset in part by increased sales to our scientific research end market.

The decreases in sales to customers in other parts of Europe and in Japan for the three months ended March 30, 2013 compared with the corresponding prior year period were due to lower sales to our scientific research end market and our industrial manufacturing and other end markets. In other parts of Europe, such decreases were offset in part by increased sales to our life and health sciences end market.

The decreases in sales to customers in other parts of the Pacific Rim and to customers in the rest of the world for the three months ended March 30, 2013 compared with the corresponding prior year period were attributable primarily to lower sales to our scientific research and microelectronics end markets, offset in part by increased sales to customers in our life and health sciences end market.

**Gross Margin**

Gross margin was 41.6% and 43.3% for the three months ended March 30, 2013 and March 31, 2012, respectively. Gross margin decreased in all of our operating groups, which was due to decreased absorption of manufacturing overhead resulting from our lower overall sales and production levels, and a lower proportion of sales of higher margin products. In addition, gross margin for the three months ended March 31, 2012 was positively impacted by higher sales of lasers inventory that had previously been written down.

In general, we expect that our gross margin will vary in any given period depending upon factors such as our mix of sales, product pricing variations, manufacturing absorption levels, and changes in levels of inventory and warranty reserves.

**Selling, General and Administrative (SG&A) Expenses**

SG&A expenses totaled \$37.6 million, or 28.4% of net sales, and \$44.1 million, or 28.0% of net sales, for the three months ended March 30, 2013 and March 31, 2012, respectively. The decrease in SG&A expenses in absolute dollars in the current year period compared with the prior year period was due primarily to a \$3.3 million reduction in amortization expense resulting from the write off of certain intangible assets of our Ophir subsidiaries during the fourth quarter of 2012 and a \$3.2 million decrease in personnel costs resulting primarily from lower incentive compensation accruals and headcount reductions as part of our 2012 cost reduction initiative.

In general, we expect that SG&A expenses will vary as a percentage of net sales in the future based on our sales level in any given period. Because the majority of our SG&A expenses is fixed in the short term, changes in SG&A expenses will likely not be in proportion to changes in net sales. In addition, any acquisitions would increase our SG&A expenses, and such increases may not be in proportion to the changes in net sales.

Table of Contents

***Research and Development (R&D) Expense***

R&D expense totaled \$13.1 million, or 9.9% of net sales, and \$13.8 million, or 8.8% of net sales, for the three months ended March 30, 2013 and March 31, 2012, respectively. The decrease in R&D expense in absolute dollars in the current year period compared with the prior year period was due to headcount reductions as part of our 2012 cost reduction initiative and delayed spending on new projects and materials.

We believe that the continued development and advancement of our products and technologies is critical to our success, and we intend to continue to invest in R&D initiatives, while working to ensure that our efforts are focused and the resources are deployed efficiently. In general, we expect that R&D expense as a percentage of net sales will vary in the future based on our sales level in any given period. Because of our commitment to continued product development, and because the majority of our R&D expense is fixed in the short term, changes in R&D expense will likely not be in proportion to changes in net sales. In addition, any acquisitions would increase our R&D expenses, and such increases may not be in proportion to the changes in net sales.

***Interest and Other Expense, Net***

Interest and other expense, net totaled \$2.1 million and \$2.2 million for the three months ended March 30, 2013 and March 31, 2012, respectively. The decrease in interest and other expense, net for the three months ended March 30, 2013 compared with the same period in 2012 was due primarily to lower interest expense as a result of the repayment of our convertible notes in February 2012 and lower interest expense on our term loan, resulting from the lower loan balance in the current year period. This decrease was offset in part by lower gains on derivative instruments in the 2013 period compared with the 2012 period.

***Income Taxes***

Our effective tax rate reflects a tax benefit on income of 19.6% and a tax expense of 17.9% for the three months ended March 30, 2013 and March 31, 2012, respectively. Our effective tax rate for the three months ended March 30, 2013 was favorably impacted by the retroactive extension of the federal research credit for 2012, which was signed into law on January 2, 2013 and the reversal of an uncertain foreign tax position related to a Japanese subsidiary, due to the expiration of the applicable audit statute of limitations.

***Liquidity and Capital Resources***

Our cash and cash equivalents, restricted cash and marketable securities balances decreased to a total of \$96.2 million as of March 30, 2013 from \$100.4 million as of December 29, 2012. This decrease was attributable primarily to cash used for net repayments of debt, purchases of property and equipment and annual incentive compensation payouts, offset in part by cash provided by other operating activities and proceeds from the issuance of common stock under employee stock plans.

## Edgar Filing: NEWPORT CORP - Form 10-Q

Net cash provided by our operating activities of \$7.5 million for the three months ended March 30, 2013 was attributable primarily to cash provided by our results of operations, offset in part by a decrease in accrued payroll and related expenses of \$2.4 million due primarily to annual incentive compensation payouts, an increase in gross inventory of \$2.4 million and a decrease in accounts receivable of \$1.8 million due to lower sales and the timing of collections.

Net cash used in investing activities of \$4.9 million for the three months ended March 30, 2013 was attributable to purchases of property and equipment of \$4.0 million and net purchases of marketable securities of \$0.9 million.

Net cash used in financing activities of \$7.2 million for the three months ended March 30, 2013 was attributable to net repayments of borrowings of \$11.2 million, which consisted primarily of principal payments on the term loan under our secured credit facility, offset in part by proceeds of \$4.0 million from the sale of stock under employee plans.

Table of Contents

In October 2011, we entered into a credit agreement with certain lenders (Credit Agreement). The Credit Agreement and the related security agreement provide for a senior secured credit facility consisting of a \$185 million term loan and a \$65 million revolving line of credit, each with a term of five years. The credit facility is secured by substantially all of our domestic assets as well as a pledge of certain shares of our subsidiaries. At March 30, 2013, we had a remaining balance of \$159.6 million outstanding on the term loan, with an effective interest rate of 2.95%. At March 30, 2013, there was no balance outstanding under the revolving line of credit, with \$63.6 million available for borrowing after considering outstanding letters of credit totaling \$1.4 million. Our ability to borrow funds under the revolving line of credit is subject to certain conditions, including compliance with certain covenants and making certain representations and warranties.

During 2011, we issued 200 million yen (\$2.1 million at March 30, 2013) in private placement bonds through a Japanese bank. These bonds bear interest at a rate of 0.62% per year, payable in cash semiannually in arrears on June 30 and December 31 of each year, and mature on June 30, 2014. The bonds are included in *long-term debt* in the accompanying consolidated balance sheets.

At March 30, 2013, we had (i) four revolving lines of credit with Japanese banks; (ii) two agreements with Japanese banks under which we sell trade notes receivable with recourse; (iii) six loans with Japanese banks; and (iv) three loans with Israeli banks, as follows:

| Description                                 | Principal                    | Amount                     |                  |  | Expiration Date(s)                  |
|---|------------------------------|----------------------------|------------------|--|-------------------------------------|
|   | Amount                       | Available for              |                  |  |                                     |
|   | Outstanding<br>(in millions) | Borrowing<br>(in millions) | Interest Rate(s) |  |                                     |
| Japanese lines of credit                    | \$ 5.3                       | \$ 5.8                     | 1.18% to 2.475%  |  | Various dates through July 2013     |
| Japanese agreements for sale of receivables | \$ 0.6                       | \$ 5.3                     | 1.48%            |  | No expiration dates                 |
| Japanese loans                              | \$ 0.9                       | \$ -                       | 1.25% to 1.45%   |  | Various dates through November 2016 |
| Israeli loans                               | \$ 3.2                       | \$ -                       | 2.97% to 3.75%   |  | Various dates through October 2015  |

In May 2008, our Board of Directors approved a share repurchase program, authorizing the purchase of up to 4.0 million shares of our common stock. No purchases were made under this program during the three months ended March 30, 2013. As of March 30, 2013, 3.9 million shares remained available for purchase under the program. However, the terms of the Credit Agreement restrict our ability to purchase additional shares under this program during the term of the Credit Agreement.

During the remainder of 2013, we expect to use \$10 million to \$12 million of cash for capital expenditures.

We believe that our current working capital position, together with our expected future cash flows from operations and the borrowing availability under our lines of credit, will be adequate to fund our operations in the ordinary course of business, our anticipated capital expenditures, our debt payment requirements and other contractual obligations for at least the next twelve months. However, this belief is based upon many assumptions and is subject to numerous risks, including those discussed in Item 1A (Risk Factors) of Part I of our Annual Report on Form 10-K for the year ended December 29, 2012.



## Edgar Filing: NEWPORT CORP - Form 10-Q

Except for the aforementioned capital expenditures, we have no present agreements or commitments with respect to any material acquisitions of businesses, products, product rights or technologies or any other material capital expenditures. We will continue to evaluate acquisitions of and/or investments in products, technologies, capital equipment or improvements or companies that complement our business and may make such acquisitions and/or investments in the future. However, the Credit Agreement only permits us to make investments and acquisitions under certain circumstances, and restricts our ability to incur additional indebtedness, which limits our ability to make such acquisitions and investments.

Table of Contents

**Recent Accounting Pronouncements**

In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2013-02, *Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income*, which requires companies to disclose significant amounts that have been reclassified out of accumulated other comprehensive income. Amounts that are required to be reclassified in their entirety to net income must be disclosed either on the face of the income statement or in the notes to the financial statements. Amounts that are not required to be reclassified in their entirety to net income in the same reporting period must be disclosed by a cross reference to other disclosures that provide additional information regarding such amounts. ASU No. 2013-02 is effective for fiscal years and interim periods beginning after December 15, 2012. The adoption of ASU No. 2013-02 has not had a material impact on our financial position or results of operations.

In March 2013, the FASB issued ASU No. 2013-05, *Foreign Currency Matters: Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity*, which clarifies the guidance in Topics 810 and 830. Topic 810 requires companies to deconsolidate a subsidiary or derecognize a group of assets if the parent ceases to hold a controlling financial interest in that subsidiary or group of assets. Upon the loss of a controlling financial interest, the parent would release the cumulative translation adjustment into net income. The guidance in Topic 810 does not distinguish between a sale or transfer of an investment *in* a foreign entity and a sale or transfer of a subsidiary or group of assets *within* a foreign entity. Topic 830 requires the release of the cumulative translation adjustment into net income if a sale or transfer represented a complete or substantially complete liquidation of an investment *in* a foreign entity. ASU No. 2013-05 clarifies that companies that cease to have a controlling financial interest in a subsidiary or group of assets *within* a foreign subsidiary should release the cumulative translation adjustment into net income if the sale or transfer results in a complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. ASU No. 2013-05 will be effective for fiscal years beginning after December 15, 2013, and early adoption is permitted but has not been elected. The adoption of ASU No. 2013-05 will not have a material impact on our financial position or results of operations.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

The principal market risks (i.e., the risk of loss arising from adverse changes in market rates and prices) to which we are exposed are changes in foreign exchange rates, which may generate translation and transaction gains and losses, and changes in interest rates.

**Foreign Currency Risk**

Operating in international markets sometimes involves exposure to volatile movements in currency exchange rates. The economic impact of currency exchange rate movements on our operating results is complex because such changes are often linked to variability in real growth, inflation, interest rates, governmental actions and other factors. These changes, if material, may cause us to adjust our financing and operating strategies. Consequently, isolating the effect of changes in currency does not incorporate these other important economic factors.

We use foreign currency option and forward exchange contracts to mitigate the risks associated with certain foreign currency transactions entered into in the ordinary course of business, primarily foreign currency denominated receivables, payables and other expenses. These derivative instruments are used as an economic hedge. However, we have not elected hedge accounting treatment and therefore, all changes in

## Edgar Filing: NEWPORT CORP - Form 10-Q

value of these derivative instruments are reflected in *interest and other expense, net* in our consolidated statements of income. We do not engage in currency speculation. All of our foreign currency option and forward exchange contracts are entered into to reduce the volatility of earnings, primarily related to Israeli shekel-based expenses. If the counterparties to these contracts (typically highly rated banks) do not fulfill their obligations to deliver the contracted currencies, we could be at risk for any currency related fluctuations.

As currency exchange rates change, translation of the statements of income of international operations into U.S. dollars affects the year-over-year comparability of operating results. We do not generally hedge translation risks because cash flows from international operations are generally reinvested locally. Changes in currency exchange rates that would have the largest impact on translating our future international operating income include changes to the exchange rates of the U.S. dollar to the euro and Japanese yen.

Table of Contents

The following table provides information about our foreign currency derivative financial instruments outstanding as of March 30, 2013. The information is presented in U.S. dollars, as presented in our consolidated financial statements:

| (In thousands)   | March 30, 2013  |                      |
|--|-----------------|----------------------|
|  | Notional Amount | Average Strike Price |
| Foreign currency forward contracts<br>(Pay U.S. dollar/receive foreign currency) |                 |                      |
| Israeli Shekel   | \$ 197          | 3.81                 |
| Fair value   | \$ 8            |                      |
| Foreign currency options   |                 |                      |
| Israeli Shekel - call options  | \$ 16,079       | 3.99                 |
| Israeli Shekel - put options   | (17,409)        | 3.80                 |
| Fair value   | \$ (1,330)      |                      |
|  | \$ 592          |                      |

**Interest Rate Risk**

Our investments in cash, cash equivalents, restricted cash and marketable securities, which totaled \$96.2 million at March 30, 2013, are sensitive to changes in the general level of interest rates. In addition, certain assets related to our pension plans are sensitive to interest rates and economic conditions in Europe.

We have a term loan, which had an outstanding principal balance of \$159.6 million at March 30, 2013, and a \$65 million revolving line of credit in the United States, as well as various lines of credit, private placement bonds and other loans throughout the world, primarily in Israel and Japan. Our term loan and revolving line of credit in the United States, and many of our other borrowings, carry variable interest rates and therefore are subject to interest rate risk.

The table below presents information about our debt obligations as of March 30, 2013:

| (US\$ equivalent in thousands) | Expected Maturity Date |           |           |           |       |            |            | Total      | Fair Value |
|--------------------------------|------------------------|-----------|-----------|-----------|-------|------------|------------|------------|------------|
|                                | 2013                   | 2014      | 2015      | 2016      | 2017  | Thereafter |            |            |            |
| Debt obligations:              |                        |           |           |           |       |            |            |            |            |
| Variable rate (US\$)           | \$ 13,874              | \$ 27,748 | \$ 27,748 | \$ 90,193 | \$ -  | \$ -       | \$ 159,563 | \$ 152,451 |            |
| Weighted average interest rate | 2.95%                  | 2.95%     | 2.95%     | 2.95%     | 0.00% | 0.00%      | 2.95%      |            |            |
| Fixed rate (non-US\$)          | \$ 1,200               | \$ 3,723  | \$ 612    | \$ -      | \$ -  | \$ -       | \$ 5,535   | \$ 5,459   |            |
| Weighted average interest rate | 3.16%                  | 1.71%     | 2.97%     | 0.00%     | 0.00% | 0.00%      | 2.16%      |            |            |
| Variable rate (non-US\$)       | \$ 6,037               | \$ 232    | \$ 173    | \$ 98     | \$ -  | \$ -       | \$ 6,540   | \$ 6,596   |            |
| Weighted average interest rate | 1.92%                  | 1.65%     | 1.30%     | 1.25%     | 0.00% | 0.00%      | 1.88%      |            |            |
| Total debt obligations         | \$ 21,111              | \$ 31,703 | \$ 28,533 | \$ 90,291 | \$ -  | \$ -       | \$ 171,638 | \$ 164,506 |            |
| Weighted average interest rate | 2.67%                  | 2.80%     | 2.94%     | 2.95%     | 0.00% | 0.00%      | 2.89%      |            |            |



Table of Contents

**ITEM 4. CONTROLS AND PROCEDURES**

**(a) Evaluation of Disclosure Controls and Procedures**

Our Chief Executive Officer and our Chief Financial Officer, after evaluating our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act )) as of the end of the period covered by this Quarterly Report on Form 10-Q (the Evaluation Date ), have concluded that as of the Evaluation Date, our disclosure controls and procedures were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer where appropriate, to allow timely decisions regarding required disclosure.

**(b) Changes in Internal Control Over Financial Reporting**

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

**PART II OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

*Hudson et al. v. Spectra-Physics, Inc. et al.*

In November 2010, two former employees of Spectra-Physics, Linda Pope and Yvette Flores, together with their children, Tia Pope Hudson and Mark Flores, filed a complaint against Spectra-Physics and us in the Superior Court for Santa Clara County, California. In the action, the plaintiffs allege that between 1975 and 1985 they and their unborn children were exposed to toxic chemicals during their work at Spectra-Physics, and that Spectra-Physics failed to warn them about dangers associated with the chemicals and failed to implement adequate safeguards to protect them from the chemicals, resulting in injuries to them and their unborn children.

In November 2012, we reached an agreement with Linda Pope and Tia Pope Hudson to settle all claims related to their portion of the suit. The amount of such settlement was immaterial. In December 2012, the court denied our motions for summary judgment of Yvette and Mark Flores claims based on the statute of limitations applicable to such claims. We subsequently filed motions for summary judgment or summary adjudication of the plaintiffs remaining claims based on additional grounds, and the plaintiffs have filed a motion for summary adjudication of certain of our affirmative defenses to the plaintiffs claims, which motions are scheduled to be heard in June 2013. Trial is currently set to commence in July 2013.

Yvette and Mark Flores are seeking an aggregate of \$20.5 million in general and special damages, as well as punitive damages for each of them to be established by the trier of fact. We dispute that the plaintiffs are entitled to any damages, and it continues to believe that the plaintiffs claims are without merit and intends to continue to vigorously defend its position. Further, discovery in the action is ongoing, and the motions for summary judgment or adjudication filed by us and the plaintiffs are pending. Therefore, at this stage of the litigation, we are unable to provide an estimate of the potential exposure or the likelihood of a favorable or unfavorable outcome in this action.

**ITEM 6. EXHIBITS**

| <b>Exhibit Number</b> | <b>Description of Exhibit</b>  |
|-----------------------|--|
| 31.1                  | Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 (the Exchange Act ). |
| 31.2                  | Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.  |
| 32.1                  | Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.             |
| 32.2                  | Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.             |
| 101.INS               | XBRL Instance Document.  |

Edgar Filing: NEWPORT CORP - Form 10-Q

101.SCH XBRL Taxonomy Extension Schema Document.  
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document.  
101.DEF XBRL Taxonomy Extension Definition Linkbase Document.  
101.LAB XBRL Taxonomy Extension Label Linkbase Document.  
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.



Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: May 9, 2013

NEWPORT CORPORATION

By:

*/s/ Charles F. Cargile*  
Charles F. Cargile,  
Senior Vice President and Chief Financial  
Officer (Principal Financial Officer and Duly  
Authorized Officer)

Table of Contents

**EXHIBIT INDEX**

| <b>Exhibit Number</b> | <b>Description of Exhibit</b>  |
|-----------------------|--|
| 31.1                  | Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 (the Exchange Act ). |
| 31.2                  | Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.  |
| 32.1                  | Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.             |
| 32.2                  | Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.             |
| 101.INS               | XBRL Instance Document.  |
| 101.SCH               | XBRL Taxonomy Extension Schema Document.   |
| 101.CAL               | XBRL Taxonomy Extension Calculation Linkbase Document.   |
| 101.DEF               | XBRL Taxonomy Extension Definition Linkbase Document.  |
| 101.LAB               | XBRL Taxonomy Extension Label Linkbase Document.   |
| 101.PRE               | XBRL Taxonomy Extension Presentation Linkbase Document.  |